Moderna Shares Surge 8% on Anticipation of Melanoma Vaccine Data

Key Facts

1Moderna shares rose 8% as investors anticipate the release of full Phase 3 dataset for its mRNA-based cancer vaccine.

Moderna shares rose 8% as investors anticipate the release of the full Phase 3 dataset for its mRNA-based cancer vaccine. 247wallst.com reported that the surge is driven by market optimism surrounding the upcoming public presentation of clinical trial results for the company's melanoma treatment.

MRNA closed at $190.01 on October 2, 2026, while Pfizer (PFE) saw weaker trading relative to its October 2, 2026, close of $27.8. This divergence occurs as traders focus on the efficacy of mRNA technology in oncology, with Moderna's stock significantly outperforming pharmaceutical peers ahead of the data release.